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At the happy ending of vitreoretinal surgery 
for proliferative diabetic retinopathy, when 
all proliferative fibrovascular tissues have 
been successfully removed, panretinal 
photocoagulation is completed and there is 
no iatrogenic break, the surgeon may wonder 
whether to consider any other intervention 
before closing the case. This question arises 
in microincision vitrectomies as well as with 
traditional 20 gauge techniques. Several 
maneuvers have been proposed in the literature 
including gas-fluid exchange with a non-
expandable air-gas mixture, cryotherapy of the 
sclerotomy sites, injection of bevacizumab and/
or triamcinolone acetonide, or any combination 
thereof. Microincision vitreoretinal surgery 
may be associated with a higher incidence 
of postoperative hypotony; 1 therefore many 
surgeons prefer to perform gas-fluid exchange 
at the end of surgery. In 20 gauge vitrectomy, 
the incisions are secured with sutures and the 
chance of hypotony is low. There is no general 
agreement on the necessity of or any benefit 
from gas-fluid exchange. 
In this issue of the Journal of Ophthalmic 
and Vision Research, Farrahi and associates2 
have compared the incidence of postoperative 
vitreous hemorrhage between two groups of 
patients, 50 each, with and without gas-fluid 
exchange at the end of diabetic vitrectomy. They 
found that vitreous hemorrhage occurred less 
frequently in eyes with gas-fluid exchange as 
compared to eyes in which the vitreous cavity 
was left filled with lactated Ringer’s solution. 
The difference was statistically significant on 
the 4th and 7th postoperative days but not 4 
weeks after the operation. However, the major 
limitation to their study is not grading the 
severity of fibrovascular proliferation, and lack 
of randomization of eyes on that basis. Still, it is 
likely that gas-fluid exchange at the conclusion 
of vitrectomy may actually decrease the chance 
of postoperative hemorrhage during the early 
postoperative period. As already mentioned, 
currently there is no strong evidence for or 
against this maneuver. 
Other interventions have also been 
studied. Cryotherapy of the sclerotomy sites 
for prevention of late postoperative vitreous 
hemorrhage after diabetic vitrectomy was 
tried by Entezari and coworkers3 yielding 
no benefit. On the other hand, injection of 
bevacizumab and triamcinolone at the end of 
diabetic vitrectomy was found to reduce the 
incidence of postoperative vitreous hemorrhage 
by Park et al.4 Also in a study by Faghihi et al,5 
intravitreal injection of triamcinolone acetonide 
at the conclusion of surgery decreased the 
rate of postoperative hemorrhage. However, 
Romano and colleagues6 did not observe such 
an effect from injection of bevacizumab at the 
end of surgery.
There is no strong evidence indicating the 
necessity of any of these procedures at the end 
of diabetic vitrectomy. On a biological basis one 
would consider the injection of bevacizumab 
and/or triamcinolone acetonide to be useful 
adjuncts to surgery. Fluid-gas exchange 
also seems to be advisable in microincision 
vitrectomies. Other procedures depend on the 
individual surgeons’ discretion. Well-powered 
randomized clinical trials exploring the benefit 
of such adjunctive procedures are direly awaited 
in the ophthalmic community. 
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